Pfizer Inc. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 387 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Pfizer Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pfizer Inc. - Product Pipeline Review - 2014', provides an overview of the Pfizer Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pfizer Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pfizer Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pfizer Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pfizer Inc.'s pipeline products

Reasons to buy

- Evaluate Pfizer Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pfizer Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pfizer Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pfizer Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pfizer Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pfizer Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Pfizer Inc. Snapshot 8
Pfizer Inc. Overview 8
Key Information 8
Key Facts 8
Pfizer Inc. - Research and Development Overview 9
Key Therapeutic Areas 9
Pfizer Inc. - Pipeline Review 22
Pipeline Products by Stage of Development 22
Pipeline Products - Monotherapy 23
Pipeline Products - Combination Treatment Modalities 24
Pipeline Products - Partnered Products 25
Pipeline Products - Out-Licensed Products 28
Pfizer Inc. - Pipeline Products Glance 31
Pfizer Inc. - Late Stage Pipeline Products 31
Pfizer Inc. - Clinical Stage Pipeline Products 35
Pfizer Inc. - Early Stage Pipeline Products 39
Pfizer Inc. - Unknown Stage Pipeline Products 42
Pfizer Inc. - Drug Profiles 43
(bazedoxifene acetate + conjugated estrogens) 43
bazedoxifene acetate 45
bosutinib 46
palbociclib 48
PF-05212366 51
celecoxib 53
oxycodone hydrochloride ER 55
tafamidis meglumine 57
(oxycodone hydrochloride + naltrexone hydrochloride) ER 59
axitinib 61
bococizumab 64
crizotinib 65
dacomitinib 68
diazepam 70
ertugliflozin 71
gosogliptin 72
infliximab biosimilar 73
inotuzumab ozogamicin 74
methylphenidate hydrochloride 76
pregabalin 77
pregabalin CR 79
rituximab biosimilar 80
rivipansel sodium 81
sildenafil citrate 83
sunitinib malate 85
tofacitinib 89
trastuzumab biosimilar 93
agatolimod sodium 94
fosdagrocorat 97
gedatolisib 98
glasdegib 100
liatermin 102
MultiStem 105
PD-0360324 108
PF-00489791 109
PF-00547659 110
PF-02545920 112
PF-03446962 113
PF-03715455 114
PF-04236921 115
PF-04457845 116
PF-04634817 118
PF-04937319 119
PF-04965842 121
PF-05089771 122
PF-05175157 124
PF-05212377 125
PF-06290510 126
PF-06291874 128
PF-06425090 129
PF-06473871 130
ponezumab 131
tanezumab 133
temsirolimus 135
ziprasidone hydrochloride 137
PF-03084014 138
PF-06463922 139
adalimumab biosimilar 141
bevacizumab biosimilar 142
F8-IL10 143
HIV-1 Vaccine 144
KUX-1151 145
PD-0325901 + PF-05212384 146
PF-04895162 147
PF-04958242 148
PF-05082566 149
PF-05206388 150
PF-05230907 151
PF-05280602 152
PF-05402536 153
PF-06252616 154
PF-06260414 155
PF-06263276 156
PF-06263507 157
PF-06282999 158
PF-06293620 159
PF-06342674 160
PF-06372865 161
PF-06412562 162
PF-06413367 163
PF-06427878 164
PF-06444752 165
PF-06444753 166
PF-06480605 167
PF-06647020 168
PF-06647263 169
PF-06649751 170
PF-06650808 171
PF-06650833 172
PF-06664178 173
PF-06669571 174
PF-06678552 175
PF-06687859 176
PF-06743649 178
PF-4447943 179
AbyD-3263 180
Antibody to Antagonize IL-7 Receptor for Type 1 Diabetes 181
Biologics for Undisclosed Indication 182
Biologics to Target PCSK-9 for Undisclosed Indication 183
BRL-44408 184
CE-355621 185
GIBH-1008 186
GIBH-1010 187
GIBH-1014 188
GIBH-1018 189
GL-2045 190
HSD-621 191
Monoclonal Antibodies for Solid Tumor 192
NIC7-DT 193
NOX-B11 194
PF-06380101 195
PF-2988403 196
PF-3306138 197
PF-3826719 198
PF-3845 199
PF-4942847 200
PF-4989216 201
PF-95453 202
PNU-120596 203
Proteins to Agonize MC4R for Obesity 204
Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor 205
Small Molecule to Inhibit HPGDS for Asthma 206
Small Molecule to Inhibit Integrase for HIV 207
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections 208
Small Molecule to Modulate Androgen Receptor for Muscle Disorders 209
Small Molecules to Activate CFTR for Cystic Fibrosis 210
Small Molecules to Inhibit NMT for Malaria 211
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain 213
WAY-258131 214
Antibodies for Cancer 215
Antisense Oligonucleotide for Undisclosed Indication 216
Melanocortin Receptor 3 Agonist for Rheumatoid Arthritis and Inflammation 217
PF-00190434 218
PF-04445597 219
PF-2311200 220
PF-2345185 221
PF-2614170 222
PF-3604861 223
PF-3686093 224
PF-46396 225
Small Molecule for Neurological Disorders 226
Small Molecule to Agonize LXR for Inflammation 227
Small Molecule to Antagonize Ghrelin for Alcoholism 228
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease 229
Small Molecule to Inhibit NS5A for HCV 230
Small Molecule to Inhibit PI3K and mTOR for Cancer 231
Small Molecule to Inhibit Pin1 for Cancer 232
Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome 233
Small Molecules for Inflammatory and Orphan Diseases 234
Small Molecules for Obesity and Diabetes 235
Small Molecules for Undisclosed Indication 236
Small Molecules to Activate A1 Adenosine Receptor for Undisclosed Indication 237
Small Molecules for Gastrointestinal Disorders 238
Pfizer Inc. - Pipeline Analysis 239
Pfizer Inc. - Pipeline Products by Target 239
Pfizer Inc. - Pipeline Products by Route of Administration 245
Pfizer Inc. - Pipeline Products by Molecule Type 247
Pfizer Inc. - Pipeline Products by Mechanism of Action 249
Pfizer Inc. - Recent Pipeline Updates 255
Pfizer Inc. - Dormant Projects 303
Pfizer Inc. - Discontinued Pipeline Products 310
Discontinued Pipeline Product Profiles 315
Pfizer Inc. - Company Statement 340
Pfizer Inc. - Locations And Subsidiaries 345
Head Office 345
Other Locations & Subsidiaries 345
Appendix 371
Methodology 371
Coverage 371
Secondary Research 371
Primary Research 371
Expert Panel Validation 371
Contact Us 372
Disclaimer 372

List of Tables
Pfizer Inc., Key Information 23
Pfizer Inc., Key Facts 23
Pfizer Inc. - Pipeline by Indication, 2014 27
Pfizer Inc. - Pipeline by Stage of Development, 2014 37
Pfizer Inc. - Monotherapy Products in Pipeline, 2014 38
Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2014 39
Pfizer Inc. - Partnered Products in Pipeline, 2014 40
Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2014 41
Pfizer Inc. - Out-Licensed Products in Pipeline, 2014 43
Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 44
Pfizer Inc. - Pre-Registration, 2014 46
Pfizer Inc. - Filing rejected/Withdrawn, 2014 47
Pfizer Inc. - Phase III, 2014 48
Pfizer Inc. - Phase II, 2014 50
Pfizer Inc. - Phase I, 2014 52
Pfizer Inc. - Preclinical, 2014 54
Pfizer Inc. - Discovery, 2014 56
Pfizer Inc. - Unknown, 2014 57
Pfizer Inc. - Pipeline by Target, 2014 255
Pfizer Inc. - Pipeline by Route of Administration, 2014 261
Pfizer Inc. - Pipeline by Molecule Type, 2014 263
Pfizer Inc. - Pipeline Products by Mechanism of Action, 2014 265
Pfizer Inc. - Recent Pipeline Updates, 2014 270
Pfizer Inc. - Dormant Developmental Projects,2014 318
Pfizer Inc. - Discontinued Pipeline Products, 2014 325
Pfizer Inc., Other Locations 360
Pfizer Inc., Subsidiaries 360